| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PALO ALTO, Calif.—In a deal expected to close earlier this month, Agilent Technologies recently announced it signed a merger agreement with scientific information management company Scientific Software Inc. Financial details of the transaction were not disclosed.
 
At the heart of the deal is a suite of software products developed by Scientific Software for laboratory applications that provide everything from data collection from more than 300 different laboratory instruments, data repository management, and workflow solutions software that can help scientists both plan and automate aspects of their research.
 
"We believe that our combined product portfolios will enable customers to unify their lab needs with one software application, handling diverse data, applications and instruments from multiple vendors in a single, seamless and secure environment," says Jim Miller, director of software for Agilent's Life Sciences and Chemical Analysis business in a press relase announcing the deal. "Scientists can collaborate across laboratory operations, linking information from a wide range of instrument platforms and data sources."
 
The merger comes less than a year after the two companies entered into a co-marketing agreement that brought SSI's CyberLAB (now called Business Process Manager, or BPM) into Agilent's distribution channel.
 
"Agilent was looking for an enterprise content manager to be more competitive in the market and we were looking for a wider distribution of our products, because as successful as we have been, the Agilent brand is by far superior  our own brand name," says Soheil Saadat, former CEO and founder of SSI of the marketing deal. "Since they were in more than 100 countries and we were only in two, we gave them the license to sell our CyberLAB  product exclusively  worldwide."
 
Early on, Saadat says, the companies enjoyed a strong working relationship based on similar corporate cultures and business philosophy. During this time, Scientific Software was in the process of developing the software that is at the heart of the merger: OpenLAB, a Web services software framework that enables management of all lab instruments, electronic content and processes in a single integrated platform.
 
"During this time I was sharing with Agilent the concepts of OpenLAB which was really our major vision at Scientific Software," says Saadat. "They liked the concepts very much. But again we felt we had a wonderful product but our distribution and brand recognition would have been an issue for us if we wanted to do justice to this wonderful product."
 
After examing other options — a second marketing agreement or an OEM agreement — both Agilent and SSI decided the best path for market penetration and to round out Agilent's own informatics offerings, was to complete a merger.
 
Once the merger is completed, most of Scientific Software's 80 employees will remain at its current Pleasanton, Calif. location. In addition, SSI, which has a number of ongoing OEM relationships with other players in the industry, will continue to honor those agreements, exactly as it has in the past. Founded in 1990, Scientific Software reported sales of more than $18 million in 2004 and had turned a profit each year it was in business.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue